Ginkgo Bioworks Holdings
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
- Ticker
- DNA
- Trading on
- NYSE
- ISIN
- US37611X2099
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dr. Jason Kelly Ph.D.
- Headquarters
- 27 Drydock Avenue, Boston, MA, United States, 02210
- Employees
- 485
- Website
- ginkgo.bio
Metrics
Analyst Insights & forecasts
Based on information from 6 analysts.
Earnings per share (EPS) forecast
| Q3 • 25 | Q4 • 25 | Q1 • 26 | |
|---|---|---|---|
| Actual | -$1.45 | -$1.42 | -$1.39 |
| Expected | -$1.24 | -$1.80 | -$1.34 |
| Surprise | -16.94% | 21.11% | -3.73% |
| Missed | Beat | Current |
Financial Performance
| Q1 • 26 | Q2 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $19.5M | $20.2M | 3.50% |
| Net income | $-82.6M | $-46.7M | -43.44% |
| Profit margin | -424.09% | -231.74% | -45.36% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Ginkgo Bioworks Holdings share?
Ginkgo Bioworks Holdings shares are currently traded for undefined per share.
02How many shares does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings currently has 55.4M shares.
03Does Ginkgo Bioworks Holdings pay dividends?
No, Ginkgo Bioworks Holdings doesn't pay dividends.
04What is Ginkgo Bioworks Holdings 52 week high?
Ginkgo Bioworks Holdings 52 week high is $17.58.
05What is Ginkgo Bioworks Holdings 52 week low?
Ginkgo Bioworks Holdings 52 week low is $5.37.
06What is the 200-day moving average of Ginkgo Bioworks Holdings?
Ginkgo Bioworks Holdings 200-day moving average is $8.34.
07Who is Ginkgo Bioworks Holdings CEO?
The CEO of Ginkgo Bioworks Holdings is Dr. Jason Kelly Ph.D..
08How many employees Ginkgo Bioworks Holdings has?
Ginkgo Bioworks Holdings has 485 employees.
09What is the market cap of Ginkgo Bioworks Holdings?
The market cap of Ginkgo Bioworks Holdings is $459M.
10What is the P/E of Ginkgo Bioworks Holdings?
The current P/E of Ginkgo Bioworks Holdings is null.
11What is the EPS of Ginkgo Bioworks Holdings?
The EPS of Ginkgo Bioworks Holdings is -$5.33.
12What is the PEG Ratio of Ginkgo Bioworks Holdings?
The PEG Ratio of Ginkgo Bioworks Holdings is null.
13What do analysts say about Ginkgo Bioworks Holdings?
According to the analysts Ginkgo Bioworks Holdings is considered a sell.


